Pacira BioSciences, Inc. — Director's Dealing 2016

Apr 20, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pacira Pharmaceuticals, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2016-04-15

Reporting Person: STACK DAVID M (Director, CEO and Chairman)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-04-15	Common Stock	M	25000	$5.49	Acquired	25285	Direct
2016-04-15	Common Stock	S	18650	$63.97	Disposed	6635	Direct
2016-04-15	Common Stock	S	6350	$64.62	Disposed	285	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-04-15	Stock Option (Right to Buy)	$5.49	M	25000	Disposed	2020-12-29	Common Stock (25000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	18596	Indirect
Common Stock	1208	Indirect

Footnotes

F1: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.48 to $64.47, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.49 to $64.82, inclusive.

F4: Mr. Stack is the general partner of Stack Schroon Mohawk FLP.

F5: Mr. Stack and his wife are the owners of LCK Investment LLC.

F6: The stock option vested as to 25% of the option shares on December 29, 2011 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months.